Literature DB >> 17967298

Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.

Juliette Thariat1, Luka Milas, K Kian Ang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17967298      PMCID： PMC2097959          DOI： 10.1016/j.ijrobp.2007.06.076

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  72 in total

1.  Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer.

Authors:  Tara Beers Gibson; Aarati Ranganathan; Axel Grothey
Journal:  Clin Colorectal Cancer       Date:  2006-05       Impact factor: 4.481

2.  Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma.

Authors:  Judith Loeffler-Ragg; Martina Witsch-Baumgartner; Alexandar Tzankov; Wolgang Hilbe; Ilona Schwentner; Georg M Sprinzl; Gerd Utermann; Heinz Zwierzina
Journal:  Eur J Cancer       Date:  2005-12-01       Impact factor: 9.162

Review 3.  Epidermal growth factor receptor biology in head and neck cancer.

Authors:  Shailaja Kalyankrishna; Jennifer R Grandis
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

4.  Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.

Authors:  James R Tonra; Dhanvanthri S Deevi; Erik Corcoran; Huiling Li; Su Wang; Francine E Carrick; Daniel J Hicklin
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

5.  Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

Authors:  Barbara Burtness; Meredith A Goldwasser; William Flood; Bassam Mattar; Arlene A Forastiere
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

6.  Cancer statistics, 2006.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Carol Smigal; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2006 Mar-Apr       Impact factor: 508.702

7.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

Review 8.  Signaling through ERBB receptors: multiple layers of diversity and control.

Authors:  Carmen M Warren; Ralf Landgraf
Journal:  Cell Signal       Date:  2006-02-07       Impact factor: 4.315

9.  Phosphotyrosine interactome of the ErbB-receptor kinase family.

Authors:  Waltraud X Schulze; Lei Deng; Matthias Mann
Journal:  Mol Syst Biol       Date:  2005-05-25       Impact factor: 11.429

Review 10.  Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival.

Authors:  H-W Lo; M-C Hung
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640
View more
  14 in total

1.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

2.  Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.

Authors:  Jie Yang; Donna McEachern; Wenyan Li; Mary A Davis; Hua Li; Meredith A Morgan; Longchuan Bai; Jonathan T Sebolt; Haiying Sun; Theodore S Lawrence; Shaomeng Wang; Yi Sun
Journal:  Mol Cancer Ther       Date:  2011-01-31       Impact factor: 6.261

3.  Incidence of dermatitis in head and neck cancer patients treated with primary radiotherapy and cetuximab.

Authors:  Edgar Selzer; Susanne Liederer; Christiane Lemaire; Gerhard Kren; Dejan Radonjic; Gabriela Kornek; Thomas Knocke; Richard Pötter; Barbara Bachtiary
Journal:  Strahlenther Onkol       Date:  2011-05-16       Impact factor: 3.621

4.  Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck.

Authors:  C Matuschek; E Bölke; C Belka; U Ganswindt; M Henke; P Stegmaier; M Bamberg; S Welz; J Debus; A Gioules; A Voigt; G Volk; C Ohmann; T Wiegel; V Budach; M Stuschke; J Schipper; P A Gerber; W Budach
Journal:  Strahlenther Onkol       Date:  2013-07-05       Impact factor: 3.621

5.  Effectiveness of combined modality radiotherapy of orthotopic human squamous cell carcinomas in Nu/Nu mice using cetuximab, tirapazamine and MnSOD-plasmid liposome gene therapy.

Authors:  Michael W Epperly; Stephen Y Lai; Anthony J Kanai; Neal Mason; Brian Lopresi; Tracey Dixon; Darcy Franicola; Yunyun Niu; William R Wilson; Joel S Greenberger
Journal:  In Vivo       Date:  2010 Jan-Feb       Impact factor: 2.155

6.  Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Authors:  Xiaoshuang Niu; Chaosu Hu; Lin Kong
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-24       Impact factor: 4.553

Review 7.  Molecular biology of head and neck cancer: risks and pathways.

Authors:  Michael E Stadler; Mihir R Patel; Marion E Couch; David Neil Hayes
Journal:  Hematol Oncol Clin North Am       Date:  2008-12       Impact factor: 3.722

8.  MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.

Authors:  George Fountzilas; Anna Kalogera-Fountzila; Sophia Lambaki; Ralph M Wirtz; Angelos Nikolaou; Georgia Karayannopoulou; Mattheos Bobos; Vassiliki Kotoula; Samuel Murray; Alexandros Lambropoulos; Gerasimos Aravantinos; Konstantinos Markou; Eleni Athanassiou; Despina Misailidou; Konstantine T Kalogeras; Demosthenis Skarlos
Journal:  J Oncol       Date:  2009-12-29       Impact factor: 4.375

9.  Composites of Nucleic Acids and Boron Clusters (C2B10H12) as Functional Nanoparticles for Downregulation of EGFR Oncogene in Cancer Cells.

Authors:  Damian Kaniowski; Katarzyna Ebenryter-Olbińska; Katarzyna Kulik; Justyna Suwara; Wojciech Cypryk; Agata Jakóbik-Kolon; Zbigniew Leśnikowski; Barbara Nawrot
Journal:  Int J Mol Sci       Date:  2021-05-04       Impact factor: 5.923

Review 10.  Molecular Mechanisms of Specific Cellular DNA Damage Response and Repair Induced by the Mixed Radiation Field During Boron Neutron Capture Therapy.

Authors:  Kamila Maliszewska-Olejniczak; Damian Kaniowski; Martyna Araszkiewicz; Katarzyna Tymińska; Agnieszka Korgul
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.